Renovo Limited

Emma Atkinson

Mark William James Ferguson

Sharon O'Kane

Nick Occleston

Hugh Gerard Laverty

Phillip Mellors

The invention provides TGF-&#x3b2;3s, or fragments or derivatives thereof, wherein the alpha-helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-&#x3b2;3 comprises at least one alpha-helix-stabilizing substitution. The invention also provides TGF-&#x3b2;3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-&#x3b2;3 is replaced with Proline. Further still, the invention provides TGF-&#x3b2;3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-&#x3b2;3 and/or the Arginine residue at position (52) of full-length wild type TGF-&#x3b2;3. The invention also provides medicaments and methods of treatment using such TGF-&#x3b2;3s.

TGF-&#x3b2;3 mutants

There is provided the use of monomeric TGF-&#x3b2;s, or there fragments or derivatives, as medicaments. These medicaments preferably comprise monomeric TGF-&#x3b2;3, or fragments or derivatives thereof. The medicaments provided may be used in the acceleration of wounding and/or the inhibition of scarring, in the promotion of epithelial regeneration, or in the prevention and/or treatment of fibrotic disorders.

Growing community of inventors

Manchester, United Kingdom

Emma Atkinson